tr?id=&ev=PageView&noscript=

Diagmand (IVD Innovation Development and Upstream Solutions Conference)

28 — 29 May 2025

The Diagmand In Vitro Diagnostics Innovation and Upstream Solutions Conference, along with the 3rd IVD Upstream Industry Chain Expo, will be grandly held on May 28–29 in Suzhou, China. Centered on the theme of “Co-creation, Coexistence, and Win-Win,” the event will bring together over 100 leading industry experts to explore critical technical bottlenecks in the IVD field. The conference will offer in-depth discussions on practical strategies for cost reduction and efficiency improvement in the upstream supply chain, responses to volume-based procurement policies, and pathways for cross-border cooperation in international markets.

Visit us at booth #A25 to explore our cutting-edge solutions in molecular and immunoassays, designed to streamline assay development, eliminate cold-chain requirements, and enhance sustainability. Our extensive portfolio includes antigens, antibodies, blockers, molecular enzymes, nucleotides, and optimized mixes for qPCR, isothermal amplification, and NGS applications.

This is a unique opportunity to connect, collaborate, and stay ahead in the ever-evolving diagnostics landscape—don’t miss out!

Join Us For Our Talk

Advancing Molecular Diagnostics: Innovative Molecular Reagents for Rapid, Accessible and Patient-Centric Testing

May 28, 2025 | 17:30-18:00 Beijing Time CST | Location: Molecular POCT Forum

Join us as we explore the transformation of molecular testing from centralized laboratories to decentralized, patient-focused care, driven by groundbreaking diagnostic advancements. Discover how next-generation molecular reagents for qPCR, isothermal amplification, and NGS are paving the way for more accessible and precision medicine. Learn how leveraging alternative specimens—such as blood, urine, sputum, and stool—can streamline workflows and ensure assay stability at ambient temperatures, reducing the need for resource-intensive shipping and storage. We’ll showcase how Meridian is at the forefront of these innovations, overcoming traditional barriers and empowering diagnostic developers to accelerate the creation of sustainable solutions.

About The Speaker

Formerly employed at Takara, Zeyuan Jia is currently Meridian Life Science Molecular Business Development Manager in Beijing. With many years of experience in customer support for qPCR reagents, he brings deep technical expertise and industry insight to the role.

<b>Zeyuan Jia</b><br> Meridian Life Science Molecular Business Development Manager, China
Zeyuan Jia
Meridian Life Science Molecular Business Development Manager, China

Join Us For Our Talk

Advanced Application of Recombinant Technology in Immunodiagnostics

May 28, 2025 | 11:00-11:20 Beijing Time CST | Location: Immunoassay Forum

The IVD industry is placing increasing emphasis on sustainability, with growing demands for energy efficiency, environmental protection, and the reduction of animal use. In the field of immunodiagnostics, a key trend is the shift from animal-derived to non-animal-derived components. Join us to learn more about the use of recombinant protein technology to produce non-animal-derived antibodies and blockers, highlighting their applications and performance in immunoassays. Through case studies and technical insights, we will explore how these alternatives support both diagnostic innovation and sustainable development in the IVD sector.

About The Speaker

Lily Song holds a Master’s degree in Veterinary Medicine from Huazhong Agricultural University. She previously served as Director of the International Business Development Department at MBL IVD and as Director of International Trade at Transgene Biotech. She is currently the Immuno Business Development Manager, with an in-depth understanding of immunoassay development.

<b>Lily Song</b><br> , Meridian Life Science Immuno Business Development Manager, China
Lily Song
, Meridian Life Science Immuno Business Development Manager, China

Get In Touch With A Specialist

Get in Touch
Welcome to
logo blue

Please select your country to continue

Continue